Loading...
QGEN logo

Qiagen N.V.NYSE:QGEN 주식 보고서

시가총액 US$7.0b
주가
US$33.61
US$53.53
37.2% 저평가 내재 할인율
1Y-25.3%
7D-15.9%
포트폴리오 가치
​
보기

Qiagen N.V.

NYSE:QGEN 주식 리포트

시가총액: US$7.0b

Qiagen (QGEN) 주식 개요

Qiagen N.V.는 전 세계에 생물학적 샘플을 분자적 통찰력으로 변환하는 샘플에서 통찰력까지 솔루션을 제공합니다. 자세히 보기

QGEN 펀더멘털 분석
스노우플레이크 점수
가치 평가5/6
미래 성장1/6
과거 실적4/6
재무 건전성6/6
배당3/6

강점

공정 가치 추정치보다 낮은 44.5% 에서 거래

수익은 매년 12.54% 증가할 것으로 예상됩니다.

지난 1년간 수익이 408.3% 증가했습니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

7.17% 의 배당금은 잉여현금흐름으로 잘 충당되지 않습니다.


QGEN Community Fair Values

Create Narrative

See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 66.7% 저평가 내재 할인율
5419.8%Revenue growth p.a.
6.2k
18
0
126
3mo ago

Qiagen N.V. 경쟁사

가격 이력 및 성과

Qiagen 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$33.61
52주 최고가US$57.82
52주 최저가US$33.17
베타0.79
1개월 변동-14.52%
3개월 변동-37.42%
1년 변동-25.31%
3년 변동-33.00%
5년 변동-37.35%
IPO 이후 변동1,433.68%

최근 뉴스 및 업데이트

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion

Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.

Recent updates

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion

Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.

QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns

Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.

QGEN: Possible Sale Prospects Are Expected To Drive Future Returns

The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.

QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns

The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.

QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside

Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.

QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks

Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.

QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition

Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.

Qiagen: Takeover Optionality With A High-Quality Consumables Platform

Jan 27

QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions

Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued

Jan 07
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued

QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead

Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.

QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms

Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.

QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside

Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.

Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality

Sep 02
Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality

Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 08
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk

Aug 05
Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk

Is Qiagen (NYSE:QGEN) A Risky Investment?

May 10
Is Qiagen (NYSE:QGEN) A Risky Investment?

Analysts Are Updating Their Qiagen N.V. (NYSE:QGEN) Estimates After Its First-Quarter Results

May 10
Analysts Are Updating Their Qiagen N.V. (NYSE:QGEN) Estimates After Its First-Quarter Results

Qiagen N.V.: Some Clarity Needed Before Buying The Dip

Feb 25
User avatar

Innovative Diagnostics And Tactical Focus Poised To Propel Growth And Margin Enhancement

Expansion in diagnostics with new QIAstat panels and applications, and QuantiFERON's wider adoption following updated guidelines, aim to significantly boost revenue.

주주 수익률

QGENUS Life SciencesUS 시장
7D-15.9%-6.4%-0.2%
1Y-25.3%1.0%27.6%

수익률 대 산업: QGEN은 지난 1년 동안 1%의 수익을 기록한 US Life Sciences 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: QGEN은 지난 1년 동안 27.6%를 기록한 US 시장보다 저조한 성과를 냈습니다.

주가 변동성

Is QGEN's price volatile compared to industry and market?
QGEN volatility
QGEN Average Weekly Movement4.7%
Life Sciences Industry Average Movement8.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.3%

안정적인 주가: QGEN는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: QGEN의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.

회사 소개

설립직원 수CEO웹사이트
19845,654Thierry Bernardwww.qiagen.com

Qiagen N.V.는 생물학적 샘플을 분자적 통찰력으로 전환하는 샘플에서 통찰력까지 솔루션을 전 세계에 제공합니다. 이 회사는 시료 재료용 핵산 안정화 및 정제 키트, 유전자형 분석, 유전자 발현, 바이러스 및 박테리아 분석을 위한 수동 및 자동화 처리, 실리카 멤브레인 및 마그네틱 비드 기술, 핵산 정제를 위한 키트 및 구성 요소를 포함한 2차 시료 기술 소모품, 핵산 정제, 품질 관리 및 액세서리용 기기 등의 시료 기술 소모품을 제공합니다. 또한 결핵 검사를 위한 인터페론-감마 방출 분석, 이식 후 검사 및 바이러스 부하 모니터링을 위한 분석 등 면역 반응 소모품, 산전 검사 및 성병 및 HPV 검출을 위한 분석, 유전체 변이 분석을 위한 분석, 진단하기 어려운 증후군의 원스텝 분자 분석 및 통합 PCR 검사를 포함한 샘플-인사이트 기기 등 다양한 소모품을 제공합니다.

Qiagen N.V. 기초 지표 요약

Qiagen의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
QGEN 기초 통계
시가총액US$7.04b
순이익 (TTM)US$424.88m
매출 (TTM)US$2.09b
16.4x
주가수익비율(P/E)
3.3x
주가매출비율(P/S)

QGEN는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
QGEN 손익계산서 (TTM)
매출US$2.09b
매출원가US$703.03m
총이익US$1.39b
기타 비용US$962.09m
순이익US$424.88m

최근 보고된 실적

Dec 31, 2025

다음 실적 발표일

May 06, 2026

주당순이익(EPS)2.05
총이익률66.36%
순이익률20.33%
부채/자본 비율44.4%

QGEN의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

배당

7.2%
현재 배당 수익률
13%
배당 성향

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/04/29 18:16
종가2026/04/29 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Qiagen N.V.는 42명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Charles ButlerBarclays